GlassScriptPhysician profile
Rea Colby
NPI 1649835968
$3,470.15
in general payments reported to CMS, 2019-2025
25 companies · $1,997 in 2025
The $1,997 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.56 · 2022: $275 · 2023: $201 · 2024: $986 · 2025: $1,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,183.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $387.69 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $327.11 | 2024-2025 | |
| Boston Scientific Corporation | $304.03 | 2022-2025 | Ams 700, Watchman Flx |
| Novo Nordisk INC | $286.68 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $267.69 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $219.28 | 2022-2025 | Arexvy, Shingrix |
| Abbvie INC. | $204.49 | 2021-2025 | |
| Lilly USA, LLC | $200.49 | 2024-2025 | Mounjaro, Zepbound, Kisunla |
| Abbott Laboratories | $191.68 | 2022-2023 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $158.36 | 2025 | Auvelity |
| Kyowa Kirin, INC. | $120.54 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $114.14 | 2025 | Austedo Xr |
| Acadia Pharmaceuticals INC | $97.44 | 2024 | Daybue |
| W. L. Gore & Associates, INC. | $91.98 | 2024 | Gore Viabahn Endoprosthesis With Heparin |
| Exact Sciences Corporation | $90.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $88.53 | 2025 | Barostim Neo System |
| Pfizer INC. | $78.48 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.60 | 2022 | |
| Currax Pharmaceuticals LLC | $42.61 | 2025 | Contrave |
| Coloplast Corp | $38.55 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.09 | 2024 | Rejoyn |
| Phathom Pharmaceuticals, INC. | $21.61 | 2024 | Voquezna |
| Organon LLC | $21.09 | 2025 | Nexplanon |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Smith+Nephew, INC. | $20.38 | 2025 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rea Colby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.